Patient Reported Outcomes of a Randomized, Placebo-Controlled Trial of Bevacizumab in the Front-Line Treatment of Ovarian Cancer: A Gynecologic Oncology Group Study

PURPOSE: To analyze quality of life (QOL) in a randomized, placebo-controlled phase III trial concluding that the addition of concurrent and maintenance bevacizumab (Arm 3) to carboplatin and paclitaxel prolongs progression-free survival in front-line treatment of advanced ovarian cancer compared to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Monk, Bradley J., Huang, Helen Q., Burger, Robert A., Mannel, Robert S., Homesley, Howard D., Fowler, Jeffrey, Greer, Benjamin E., Boente, Matthew, Liang, Sharon X., Wenzel, Lari
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4099057/
https://ncbi.nlm.nih.gov/pubmed/23219660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2012.11.038
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados